Organised aesthetic clinics set to gain from tighter rules on Botox

CDSCO's move can lead to the formalisation of more than 35,000 skin clinics, stop the mushrooming of single-operator setups run by unqualified practitioners

India’s ₹700 crore aesthetic injectables segment is bracing for a shakeup, with organised dermatology and skin clinic chains expecting tighter regulatory scrutiny of botox, hyaluronic acid fillers, and skin boosters to quicken consumer migration towards medically supervised clinics. 

The shift follows a clarification by the Central Drugs Standard Control Organisation (CDSCO) that injectable products cannot be treated as ordinary cosmetics and must instead fall under stricter medical and drug-related oversight.

 

Industry executives told Business Standard that the move could formalise a rapidly expanding aesthetics market, where demand for facial rejuvenation, anti-ageing procedures, and skin enhancement treatments has surged across urban India.

 

“Aesthetic procedures are becoming increasingly mainstream, driven by social media influence, rising disposable incomes, and growing acceptance of preventive and appearance-enhancing non-surgical treatments among younger consumers,” a Delhi-based dermatologist said.

 

Estimated at $ 81.9 million (₹680 crore-700 crore) in 2025, India’s aesthetic injectables market is projected to expand at a compound annual growth rate of over 12 per cent to reach $ 205.5 million by 2033, according to Grand View Research. “India’s aesthetic injectables market is still smaller than mature global markets, but it is growing rapidly,” said Rishi Agrawal, cofounder and chief executive officer of TeamLease RegTech.

 

Medical experts, however, said the CDSCO’s move did not ban injectable aesthetic procedures when performed by qualified dermatologists or plastic surgeons using approved products. 

Instead, the move primarily targets unregulated operators, salons, and informal wellness centres administering injectable procedures outside proper medical oversight. 

 

“Now you cannot market injectables under cosmetic products, but doctors in licensed clinics such as plastic surgeons or dermatologists can still inject botox or fillers because these are approved under CDSCO norms,” said Anmol Chugh, associate director at the Plastics & Aesthetics Centre at Gurugram’s CK Birla Hospital.

 

CDSCO peel-back lays bare grey-market operators 

Doctors said the CDSCO intervention comes amid growing concerns over aggressive social media marketing and the increasing normalisation of injectable beauty procedures outside clinical environments. “Treatments that once existed largely inside medical settings are now marketed almost like lifestyle services,” Agrawal said. 

This has led to the rise of several “mom-and pop-stores” run by unqualified individuals and doctors with no dermatology training, offering procedures such as chemical peels, skin-lightening therapies, and fillers. “Short-term, even day-long certificate courses costing anywhere from a few thousand rupees to ₹1-2 lakh from non-credible institutions have become the only credential standing between a patient’s face and a syringe,” said Geoffrey Vaz, dermatologist and founder of Maven Esthetics. 

Amit Jain, dermatologist at Dr Jain’s Skin Care Clinic in Pune, said the CDSCO’s move will affect local skin clinics that were offering aesthetic services through unethical marketing practices. This, he said, could benefit organised clinic chains and certified dermatologists as consumers increasingly prioritise safety, traceability, and qualified practitioners over low-cost procedures. 

Industry players said many aesthetic businesses expanded during a period when market growth outpaced regulation, resulting in uneven compliance standards across clinics, suppliers, and distributors. 

Doctors said injectable cosmetic products, including botox, dermal fillers, glutathione drips, and skin boosters, involve substances entering the body through injections and therefore carry medical risks if improperly administered. Complications can include allergic reactions, infections, filler migration, vascular blockage, facial asymmetry, nerve damage and, in rare cases, blindness. 

Industry observers added that the clarification could bring greater scrutiny to products such as glutathione injections, skin-brightening therapies, vitamin drips, mesotherapy preparations, and other injectable aesthetic treatments that have often been marketed through wellness clinics and beauty centres.

 

CDSCO moves needle on 35,000 clinics 

Industry executives said the biggest challenge now will be enforcement across more than 35,000 skin clinics in the country, 90 per cent of which are unorganised and dominated by solo practitioners. 

While organised clinics and qualified practitioners largely operate within existing medical frameworks, regulators will need to monitor a large number of standalone beauty clinics, salons, and wellness centres offering injectable procedures across cities. 

Clinics will now be expected to maintain stronger documentation around product sourcing, informed patient consent, prescribing physicians, batch traceability and practitioner qualifications. “Anything that you inject cannot be classified as a cosmetic. It has to be treated as a drug-device-based medical procedure,” Chugh said. 

The clarification is also expected to have implications for importers, distributors, and marketers of aesthetic products, particularly around product registration, sourcing, traceability, and promotional claims. Industry participants said compliance requirements could increase across the supply chain as regulators tighten oversight. 

For importers, the biggest impact may be around product classification and regulatory approvals. “If a product is injectable, regulators may increasingly expect it to be evaluated through the appropriate drug or medical regulatory pathway rather than being marketed under the cosmetics framework,” Agrawal said. 

Similarly, smaller distributors, traders, and parallel import networks operating with limited regulatory documentation or sourcing products through informal international channels may face increased enforcement risks. “As a result, the regulation may affect businesses operating through e-commerce platforms, wellness and beauty product aggregators, and social media-led sales models,” a Delhi-based dermatologist told Business Standard.

 

India’s aesthetics boom shows no wrinkles yet 

Demand for injectable cosmetic procedures, however, is expected to remain upbeat. Doctors said younger consumers are opting for preventive aesthetic treatments in their twenties, while the core demand continues to come from those aged 30 to 50 years. 

“The demand is increasing daily,” Chugh said, adding that women and younger men alike are increasingly opting for minimally invasive cosmetic procedures. 

Jain said growing awareness, rising affordability, and wider acceptance of cosmetic dermatology are likely to continue driving demand across India despite tighter regulation. 

Doctors and industry executives also pointed to a growing overlap between rapid weightloss therapies such as glucagon-like peptide-1 (GLP-1) drugs and demand for facial rejuvenation treatments. Rapid weightloss can lead to facial hollowing and skin laxity, increasing demand for fillers, collagen-stimulating procedures, and skin-tightening therapies. 

Several dermatologists said the phenomenon, often referred to internationally as ‘Ozempic face’, has contributed to higher demand for facial volume restoration procedures among patients undergoing rapid weight loss. “Patients on GLP-1 drugs who lose 12 to 15 kilograms within a short period are presenting with a very specific and challenging aesthetic picture. These include hollowed temples, deflated cheeks, deepened nasolabial folds, periorbital volume loss, and skin that has lost its structural scaffolding faster than it can adapt,” Vaz said. 

He added that social media trends and rapid adoption of GLP-1 weightloss drugs are together reshaping aesthetic medicine demand patterns globally and in India, with such treatments often being pursued aggressively by unqualified centres without adequate pre-treatment counselling on aesthetic consequences. “This has led to higher demand for collagen-stimulating treatments, facial rejuvenation, fillers, biostimulatory injectables, and skin-tightening procedures,” he added. 

Industry executives said the CDSCO clarification may initially increase compliance costs and disrupt informal operators, but could ultimately strengthen consumer trust and accelerate the formalisation of India’s aesthetic medicine market. 

Debraj Shome, director and cofounder of The Esthetic Clinics, said the clarification comes at a critical stage in India’s healthcare and wellness evolution as the country’s beauty, wellness, and aesthetics industry continues to expand rapidly. “As markets mature, regulation naturally becomes more sophisticated,” Shome said. “Strong but practical regulation can help the sector grow sustainably by improving consumer confidence and encouraging responsible businesses.” 

Agrawal said the aesthetics industry has operated in a regulatory grey zone for years, with CDSCO essentially signalling that this middle ground cannot remain undefined forever.

 

More skin in the game

 

$81.9 million (₹680-700 crore): Size of India’s injectable aesthetics market in 2025 

$205.5 million: Expected market size by 2033 

Around 35,000 skin clinics in India, most run by solo practitioners 

Formalisation push: Around 90% of skin clinics operate in unorganised sector 

30-50 years: Core consumer age group for injectable aesthetic procedures 

Rising GLP-1 usage and ‘Ozempic face’ driving demand for facial rejuvenation treatments